These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 9040721)

  • 1. Long-term effects of tetrabenazine in hyperkinetic movement disorders.
    Jankovic J; Beach J
    Neurology; 1997 Feb; 48(2):358-62. PubMed ID: 9040721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias.
    Jankovic J; Orman J
    Neurology; 1988 Mar; 38(3):391-4. PubMed ID: 3279337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders.
    Kenney C; Hunter C; Jankovic J
    Mov Disord; 2007 Jan; 22(2):193-7. PubMed ID: 17133512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetrabenazine treatment in movement disorders.
    Paleacu D; Giladi N; Moore O; Stern A; Honigman S; Badarny S
    Clin Neuropharmacol; 2004; 27(5):230-3. PubMed ID: 15602104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tetrabenazine.
    Fasano A; Bentivoglio AR
    Expert Opin Pharmacother; 2009 Dec; 10(17):2883-96. PubMed ID: 19929707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.
    Chen JJ; Ondo WG; Dashtipour K; Swope DM
    Clin Ther; 2012 Jul; 34(7):1487-504. PubMed ID: 22749259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tetrabenazine in the treatment of hyperkinetic movement disorders.
    Kenney C; Jankovic J
    Expert Rev Neurother; 2006 Jan; 6(1):7-17. PubMed ID: 16466307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study.
    Jankovic J
    Ann Neurol; 1982 Jan; 11(1):41-7. PubMed ID: 6460467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha methylparatyrosine and tetrabenazine in movement disorders.
    Lang AE; Marsden CD
    Clin Neuropharmacol; 1982 Dec; 5(4):375-87. PubMed ID: 6130839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders.
    Jankovic J; Clarence-Smith K
    Expert Rev Neurother; 2011 Nov; 11(11):1509-23. PubMed ID: 22014129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.
    Guay DR
    Am J Geriatr Pharmacother; 2010 Aug; 8(4):331-73. PubMed ID: 20869622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tetrabenazine therapy of pediatric hyperkinetic movement disorders.
    Jain S; Greene PE; Frucht SJ
    Mov Disord; 2006 Nov; 21(11):1966-72. PubMed ID: 16958131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long-term effect of tetrabenazine in the management of Huntington disease.
    Fasano A; Cadeddu F; Guidubaldi A; Piano C; Soleti F; Zinzi P; Bentivoglio AR
    Clin Neuropharmacol; 2008; 31(6):313-8. PubMed ID: 19050408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol.
    Ondo WG; Hanna PA; Jankovic J
    Am J Psychiatry; 1999 Aug; 156(8):1279-81. PubMed ID: 10450276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial.
    Huntington Study Group
    Neurology; 2006 Feb; 66(3):366-72. PubMed ID: 16476934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term effects of tetrabenazine on chorea associated with Huntington's disease.
    Kenney C; Hunter C; Davidson A; Jankovic J
    Mov Disord; 2007 Jan; 22(1):10-3. PubMed ID: 17078062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia.
    Fernandez HH; Stamler D; Davis MD; Factor SA; Hauser RA; Jimenez-Shahed J; Ondo WG; Jarskog LF; Woods SW; Bega D; LeDoux MS; Shprecher DR; Anderson KE
    J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1317-1323. PubMed ID: 31296586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of CYP2D6 genotype and response to tetrabenazine.
    Mehanna R; Hunter C; Davidson A; Jimenez-Shahed J; Jankovic J
    Mov Disord; 2013 Feb; 28(2):210-5. PubMed ID: 23280482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine depleters in the treatment of hyperkinetic movement disorders.
    Jankovic J
    Expert Opin Pharmacother; 2016 Dec; 17(18):2461-2470. PubMed ID: 27819145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic use of tetrabenazine].
    López Del Val LJ; López-García E; Martínez-Martínez L; Santos-Lasaosa S
    Rev Neurol; 2009 May 16-31; 48(10):523-33. PubMed ID: 19434587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.